A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in patients with cognitive impairment due to Alzheimer¿s Disease.

Boehringer Ingelheim Ellas AE0 个研究点目标入组 750 人开始时间: 2016年5月18日最近更新: 2020年2月1日

试验速览

暂无简介。

•- Patients with early signs of dementia of Alzheimer Type
•- Male and female patients with an age of at least 55 years
•- Concomitant use of AChEIs is allowed but not required. Patients who are currently taking AChEIs are eligible as long as they have been using a stable dose for at least 3 months prior to screening and no change is foreseen for the duration of the study. This dose must be consistent with the product label in the concerned country. Patients who are not currently taking AChEIs but have taken them in the past are also eligible if AChEIs were stopped at least 3 months prior to screening.
•- Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient and documented by the study investigator.
•- Patients must have a reliable study partner (per investigator judgement, for instance a family member, partner etc., guardian or, if applicable, a legal representative)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 293
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 292

•- Cognitive impairment or dementia with any etiology other than dementia of Alzheimer Type
•- Substantial concomitant cerebrovascular disease (defined by a history of a stroke / intracranial haemorrhagia) temporally related to the onset of worsening of cognitive impairment per investigator judgement
•- Medical history or diagnosis of any of symptomatic and unstable/uncontrolled conditions per investigator judgement
•- Patients receiving prescribed drugs for treatment of dementia of Alzheimer Type (other than Acetylcholine Esterase Inhibitors) at screening or within 3 months prior to screening
•- Any other psychiatric disorders such as schizophrenia, or mental retardation
•- Previous participation in investigational drug studies of mild cognitive impairment/DAT within three months prior to screening. Having received active treatment in any other study targeting disease modification of AD like Aß immunization and tau therapies. Previous participation in studies with non-prescription medications, vitamins or other nutritional formulations is allowed.
•- Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.

发起方

Boehringer Ingelheim Ellas AE